Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH Study-Reference-Cited by-同舟云学术

Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH Study

Published:2016-05 Issue:5 Volume:16 Page:286-296
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Cortes Jorge E.,Lipton Jeffrey H.,Miller Carole B.,Busque Lambert,Akard Luke P.,Pinilla-Ibarz Javier,Keir Christopher,Warsi Ghulam,Lin Felice P.,Mauro Michael J.

Funder

Novartis Pharmaceuticals Corporation

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference32 articles.

1. Managing side effects of tyrosine kinase inhibitor therapy to optimize adherence in patients with chronic myeloid leukemia: the role of the midlevel practitioner;Cornelison;J Support Oncol,2012

2. Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib;Efficace;Leukemia,2013

3. Measuring the symptom burden associated with the treatment of chronic myeloid leukemia;Williams;Blood,2013

4. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study;Noens;Blood,2009

5. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy;Ibrahim;Blood,2011

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2024-02

2. The effect of imatinib and nilotinib on blood calcium and blood potassium levels in chronic myeloid leukemia patient: a literature review;Oncology Reviews;2021-11-26

3. Chronic myeloid leukaemia;The Lancet;2021-11

5. Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase Inhibitors;JNCI: Journal of the National Cancer Institute;2021-09-07